MTP-101-C
Phase 2Biologic
MTP-101-C is one of 25 biologic programs targeting Colitis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
41 competitors in Colitis
#DrugCompanyPhaseTrials
1Simponi
Johnson & JohnsonApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Imuran
LLegacy Health System
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Medrol
PfizerPhase 3
Dificlir
Merck & Co.Phase 3
Remicade
OOrganon and Co
Phase 3
Stelara
Johnson & JohnsonPhase 3
Bismuth Subsalicylate
BiogenApproved
Entyvio
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MTP-101-C. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- DDiwakar Davar